86 related articles for article (PubMed ID: 3484663)
21. Demonstration of the increase in serine esterase-positive T cells in hairy-cell leukemia patients undergoing alpha-interferon therapy.
Wagner L; Goldstone AH; Worman CP
Leukemia; 1989 May; 3(5):373-9. PubMed ID: 2497282
[TBL] [Abstract][Full Text] [Related]
22. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
23. Abnormally activated T lymphocytes in the spleen of patients with hairy-cell leukemia.
Kluin-Nelemans JC; Kester MG; Oving I; Cluitmans FH; Willemze R; Falkenburg JH
Leukemia; 1994 Dec; 8(12):2095-101. PubMed ID: 7807997
[TBL] [Abstract][Full Text] [Related]
24. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
[TBL] [Abstract][Full Text] [Related]
25. Hairy cell leukaemia: observations on natural killer activity in different clinical stages of the disease.
Demeter J; Pálóczi K; Lehoczky D; Benczúr M
Br J Haematol; 1989 Feb; 71(2):239-44. PubMed ID: 2923810
[TBL] [Abstract][Full Text] [Related]
26. Modulation of immune functions by long-term treatment with recombinant interferon-alpha 2 in a patient with hairy-cell leukemia.
Teichmann JV; Sieber G; Ludwig WD; Ruehl H
J Interferon Res; 1988 Feb; 8(1):15-24. PubMed ID: 3259251
[TBL] [Abstract][Full Text] [Related]
27. Role of CD16 (Fc receptor III) and interleukin-2 in the reactivation of natural killer cells after inhibitory target cell contact.
Heiskala M; Ståhls A; Seppälä I; Timonen T
Nat Immun Cell Growth Regul; 1991; 10(5):265-77. PubMed ID: 1836835
[TBL] [Abstract][Full Text] [Related]
28. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients.
Brenner BG; McCrea EL; Margolese RG
Anticancer Res; 1988; 8(4):653-8. PubMed ID: 3263077
[TBL] [Abstract][Full Text] [Related]
29. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
[TBL] [Abstract][Full Text] [Related]
30. Natural killer cells in children with acute leukemia. The effect of interleukin-2.
Mageed AA; Findley HW; Franco C; Singhapakdi S; Alvarado C; Chan WC; Ragab AH
Cancer; 1987 Dec; 60(12):2913-8. PubMed ID: 3499970
[TBL] [Abstract][Full Text] [Related]
31. Functional impairment of natural killer cells in active ulcerative colitis: reversion of the defective natural killer activity by interleukin 2.
Manzano L; Alvarez-Mon M; Abreu L; Antonio Vargas J; de la Morena E; Corugedo F; Duràntez A
Gut; 1992 Feb; 33(2):246-51. PubMed ID: 1541421
[TBL] [Abstract][Full Text] [Related]
32. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
Kawakami Y; Custer MC; Rosenberg SA; Lotze MT
J Immunol; 1989 May; 142(10):3452-61. PubMed ID: 2654291
[TBL] [Abstract][Full Text] [Related]
33. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2.
Uharek L; Zeis M; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N; Müller-Ruchholtz W
Leukemia; 1996 Nov; 10(11):1758-64. PubMed ID: 8892679
[TBL] [Abstract][Full Text] [Related]
34. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia.
Foa R; Fierro MT; Lusso P; Bonferroni M; Raspadori D; Buzzi M; Zinzani PL; Resegotti L; Lauria F
Leukemia; 1987 Apr; 1(4):377-9. PubMed ID: 3499543
[TBL] [Abstract][Full Text] [Related]
35. Modulation of in vitro porcine natural killer cell activity by recombinant interleukin-1 alpha, interleukin-2 and interleukin-4.
Knoblock KF; Canning PC
Immunology; 1992 Jun; 76(2):299-304. PubMed ID: 1634252
[TBL] [Abstract][Full Text] [Related]
36. G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte.
Sconocchia G; Fujiwara H; Rezvani K; Keyvanfar K; El Ouriaghli F; Grube M; Melenhorst J; Hensel N; Barrett AJ
J Leukoc Biol; 2004 Dec; 76(6):1214-9. PubMed ID: 15345723
[TBL] [Abstract][Full Text] [Related]
37. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
[TBL] [Abstract][Full Text] [Related]
38. Induction of NK and LAK activities in human lymphocyte culture by a cytosol fraction from leukemic myeloblasts and by monoclonal antibody CD 3.
Soucek J; Chudomel V; Hrubá A; Lindnerová G
Neoplasma; 1991; 38(1):33-41. PubMed ID: 2011208
[TBL] [Abstract][Full Text] [Related]
39. Cytogenetic studies of hairy cell leukemia.
Lele KP; Filippa DA; Chaganti RS
Cancer Genet Cytogenet; 1981 Dec; 4(4):325-30. PubMed ID: 7332900
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
